Symptomatic Remission in Schizophrenia: Results from a Risperidone Maintenance Treatment Study
2017
Abstract This study aimed to investigate remission following the treatment of schizophrenia patients with risperidone. Clinically stabilized patients with schizophrenia (n = 374) were randomly assigned to 4-week, 26-week, or no-dose-reduction groups, in which the baseline risperidone dose was continued for 4, 26, or all weeks during 1-year period. The ‘Positive and Negative Syndrome Scale’ (PANNS) was assessed at baseline and monthly for six months, followed by every two months until the last recruited patient completed 1-year follow-up. Symptomatic remission was defined according to criteria established by the Schizophrenia Working Group. A Generalized Linear Mixed Model indicated significant variation in remission over time, which increased after baseline in the entire group (F = 49.32, df = 1, 3114, P
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
31
References
0
Citations
NaN
KQI